Expression of the PAX8/PPARγ Fusion Protein Is Associated with Decreased Neovascularization In Vivo: Impact on Tumorigenesis and Disease Prognosis.

The PAX8/PPARγ fusion protein (PPFP) occurs in 36% of human follicular thyroid carcinoma (FTC) and is associated with favorable prognosis. To elucidate the function of PPFP in FTC, we analyzed the consequences of PPFP expression in immortalized thyrocytes in vitro and in vivo via xenograft tumorigenesis. While PPFP-expressing cells exhibited oncogenic hallmarks, including increased growth and decreased apoptosis, in vitro, xenograft tumors were initiated but not sustained in vivo. PPFP xenograft tumors exhibited reduced CD31 staining and VEGF expression, suggesting that PPFP modulates neovascularization. Microarray analysis demonstrated increased expression of tissue inhibitor of metalloproteinase (TIMP-3), an inhibitor of angiogenesis, in PPFP cells and tumors, a finding confirmed by quantitative PCR and immunohistochemistry. Immunohistochemical staining of archival human thyroid tumors demonstrates a significant decrease in CD31 staining in all adenomas and carcinomas containing the PAX8/PPARγ rearrangement. Decreased angiogenesis in PPFP-containing tumors is directly correlated with our observations in the xenograft model and provides evidence for the first time that PPFP may impact FTC tumorigenesis by modulating angiogenesis in vivo.

[1]  Y. Nikiforov,et al.  Mechanisms of chromosomal rearrangements in solid tumors: The model of papillary thyroid carcinoma , 2010, Molecular and Cellular Endocrinology.

[2]  N. Eberhardt,et al.  The role of the PAX8/PPARγ fusion oncogene in the pathogenesis of follicular thyroid cancer , 2010, Molecular and Cellular Endocrinology.

[3]  L. Raetzman,et al.  The notch target gene HES1 regulates cell cycle inhibitor expression in the developing pituitary. , 2009, Endocrinology.

[4]  Y. Surh,et al.  The role of 15-deoxy-delta(12,14)-prostaglandin J(2), an endogenous ligand of peroxisome proliferator-activated receptor gamma, in tumor angiogenesis. , 2008, Biochemical pharmacology.

[5]  R. Seger,et al.  PPARγ and MEK Interactions in Cancer , 2008, PPAR Research.

[6]  J. S. Rao,et al.  Tissue inhibitor of metalloproteinase 3 suppresses tumor angiogenesis in matrix metalloproteinase 2-down-regulated lung cancer. , 2008, Cancer research.

[7]  A. Banito,et al.  Aneuploidy and RAS mutations are mutually exclusive events in the development of well‐differentiated thyroid follicular tumours , 2007, Clinical endocrinology.

[8]  C. Espadinha,et al.  PAX8PPARgamma stimulates cell viability and modulates expression of thyroid-specific genes in a human thyroid cell line. , 2007, Thyroid : official journal of the American Thyroid Association.

[9]  R. DeLellis.  Pathology and genetics of thyroid carcinoma , 2006, Journal of surgical oncology.

[10]  J. Califano,et al.  Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer , 2006, International journal of cancer.

[11]  D. Greenspan,et al.  TIMP-3 inhibits the procollagen N-proteinase ADAMTS-2. , 2006, The Biochemical journal.

[12]  David E. Misek,et al.  Delineation, Functional Validation, and Bioinformatic Evaluation of Gene Expression in Thyroid Follicular Carcinomas with the PAX8-PPARG Translocation , 2006, Clinical Cancer Research.

[13]  Robert N. Taylor,et al.  PPAR$$\upgamma$$ represses VEGF expression in human endometrial cells: Implications for uterine angiogenesis , 2006, Angiogenesis.

[14]  J. Pipas,et al.  SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation , 2005, Oncogene.

[15]  S. Michiels,et al.  Tumorigenesis and Neoplastic Progression Follicular Thyroid Tumors with the PAX 8-PPAR 1 Rearrangement Display Characteristic Genetic Alterations , 2005 .

[16]  K. Bhattacharyya,et al.  Thyroid transcription factor-1 in orbital adipose tissues: potential role in orbital thyrotropin receptor expression. , 2005, Thyroid : official journal of the American Thyroid Association.

[17]  W. Hohenberger,et al.  Alterations in the tissue inhibitor of metalloproteinase-3 (TIMP-3) are found frequently in human colorectal tumours displaying either microsatellite stability (MSS) or instability (MSI). , 2005, Cancer letters.

[18]  P. Quax,et al.  Gene Transfer of Tissue Inhibitor of Metalloproteinases-3 Reverses the Inhibitory Effects of TNF-α on Fas-Induced Apoptosis in Rheumatoid Arthritis Synovial Fibroblasts1 , 2005, The Journal of Immunology.

[19]  T. Dwight,et al.  Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPARγ fusion oncogene , 2005, Oncogene.

[20]  J. Bidart,et al.  PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues. , 2004, European journal of endocrinology.

[21]  L. Sobrinho,et al.  Underexpression of peroxisome proliferator-activated receptor (PPAR)γ in PAX8/PPARγ-negative thyroid tumours , 2004, British Journal of Cancer.

[22]  N. Eberhardt,et al.  The PAX8/PPARγ fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARγ inhibition , 2004, Oncogene.

[23]  J. Foidart,et al.  Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1‐MMP, MMP‐2 and MMP‐9 in human glioblastomas , 2003, International journal of cancer.

[24]  T. Dwight,et al.  Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. , 2003, The Journal of clinical endocrinology and metabolism.

[25]  D. Albertson,et al.  Chromosome aberrations in solid tumors , 2003, Nature Genetics.

[26]  Yuri E Nikiforov,et al.  RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.

[27]  J. Garber,et al.  Genetic and biological subgroups of low-stage follicular thyroid cancer. , 2003, The American journal of pathology.

[28]  L. Claesson‐Welsh,et al.  A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2 , 2003, Nature Medicine.

[29]  Napoleone Ferrara,et al.  VEGF and the quest for tumour angiogenesis factors , 2002, Nature Reviews Cancer.

[30]  L. Sobrinho,et al.  Expression of PAX8-PPARγ1 Rearrangements in Both Follicular Thyroid Carcinomas and Adenomas , 2002 .

[31]  K. Brew,et al.  TIMP-3 Binds to Sulfated Glycosaminoglycans of the Extracellular Matrix* , 2000, The Journal of Biological Chemistry.

[32]  C. J. Chen,et al.  PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. , 2000, Science.

[33]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[34]  D. Benezra.  Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. , 1997, Investigative ophthalmology & visual science.

[35]  J. Folkman,et al.  The role of angiogenesis in tumor growth. , 1992, Seminars in cancer biology.

[36]  D. Sheer,et al.  Characterisation of human thyroid epithelial cells immortalised in vitro by simian virus 40 DNA transfection. , 1989, British Journal of Cancer.

[37]  E. Wimmer,et al.  Initiation of protein synthesis by internal entry of ribosomes into the 5' nontranslated region of encephalomyocarditis virus RNA in vivo , 1989, Journal of virology.

[38]  F. Denizot,et al.  Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. , 1986, Journal of immunological methods.

[39]  J. Folkman,et al.  TUMOR DORMANCY IN VIVO BY PREVENTION OF NEOVASCULARIZATION , 1972, The Journal of experimental medicine.

[40]  K. Kawakami,et al.  Quantitative detection of TIMP-3 promoter hypermethylation and its prognostic significance in esophageal squamous cell carcinoma. , 2008, Oncology reports.

[41]  B. Li,et al.  Inhibition of human leukemia xenograft in nude mice by adenovirus-mediated tissue inhibitor of metalloproteinase-3 , 2006, Leukemia.

[42]  Amy Y. M. Au,et al.  PAX8-Peroxisome Proliferator-Activated Receptor γ (PPARγ) Disrupts Normal PAX8 or PPARγ Transcriptional Function and Stimulates Follicular Thyroid Cell Growth , 2006 .

[43]  Amy Y. M. Au,et al.  PAX8-peroxisome proliferator-activated receptor gamma (PPARgamma) disrupts normal PAX8 or PPARgamma transcriptional function and stimulates follicular thyroid cell growth. , 2006, Endocrinology.

[44]  N. Eberhardt,et al.  PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value. , 2005, The Journal of clinical endocrinology and metabolism.

[45]  J. Soria,et al.  Oncogènes et tumeurs de la thyroïde , 2005 .

[46]  N. Eberhardt,et al.  The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition. , 2004, Oncogene.

[47]  A. Gill,et al.  Detection of the PAX8-PPARγ Fusion Oncogene in Both Follicular Thyroid Carcinomas and Adenomas , 2003 .

[48]  A. Gill,et al.  Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. , 2003, The Journal of clinical endocrinology and metabolism.

[49]  L. Sobrinho,et al.  Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. , 2002, The Journal of clinical endocrinology and metabolism.

[50]  B. Olsen,et al.  A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. , 1996, Biochemistry and cell biology = Biochimie et biologie cellulaire.